Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design. by Rachel S Gross, Tanayott Thaweethai, Erika B Rosenzweig, James Chan, Lori B Chibnik, Mine S Cicek, Amy J Elliott, Valerie J Flaherman, Andrea S Foulkes, Margot Gage Witvliet, Richard Gallagher, Maria Laura Gennaro, Terry L Jernigan, Elizabeth W Karlson, Stuart D Katz, Patricia A Kinser, Lawrence C Kleinman, Michelle F Lamendola-Essel, Joshua D Milner, Sindhu Mohandas, Praveen C Mudumbi, Jane W Newburger, Kyung E Rhee, Amy L Salisbury, Jessica N Snowden, Cheryl R Stein, Melissa S Stockwell, Kelan G Tantisira, Moriah E Thomason, Dongngan T Truong, David Warburton, John C Wood, Shifa Ahmed, Almary Akerlundh, Akram N Alshawabkeh, Brett R Anderson, Judy L Aschner, Andrew M Atz, Robin L Aupperle, Fiona C Baker, Venkataraman Balaraman, Dithi Banerjee, Deanna M Barch, Arielle Baskin-Sommers, Sultana Bhuiyan, Marie-Abele C Bind, Amanda L Bogie, Tamara Bradford, Natalie C Buchbinder, Elliott Bueler, Hülya Bükülmez, B J Casey, Linda Chang, Maryanne Chrisant, Duncan B Clark, Rebecca G Clifton, Katharine N Clouser, Lesley Cottrell, Kelly Cowan, Viren D'Sa, Mirella Dapretto, Soham Dasgupta, Walter Dehority, Audrey Dionne, Kirsten B Dummer, Matthew D Elias, Shari Esquenazi-Karonika, Danielle N Evans, E Vincent S Faustino, Alexander G Fiks, Daniel Forsha, John J Foxe, Naomi P Friedman, Greta Fry, Sunanda Gaur, Dylan G Gee, Kevin M Gray, Stephanie Handler, Ashraf S Harahsheh, Keren Hasbani, Andrew C Heath, Camden Hebson, Mary M Heitzeg, Christina M Hester, Sophia Hill, Laura Hobart-Porter, Travis K F Hong, Carol R Horowitz, Daniel S Hsia, Matthew Huentelman, Kathy D Hummel, Katherine Irby, Joanna Jacobus, Vanessa L Jacoby, Pei-Ni Jone, David C Kaelber, Tyler J Kasmarcak, Matthew J Kluko, Jessica S Kosut, Angela R Laird, Jeremy Landeo-Gutierrez, Sean M Lang, Christine L Larson, Peter Paul C Lim, Krista M Lisdahl, Brian W McCrindle, Russell J McCulloh, Kimberly McHugh, Alan L Mendelsohn, Torri D Metz, Julie Miller, Elizabeth C Mitchell, Lerraughn M Morgan, Eva M Müller-Oehring, Erica R Nahin, Michael C Neale, Manette Ness-Cochinwala, Sheila M Nolan, Carlos R Oliveira, Onyekachukwu Osakwe, Matthew E Oster, R Mark Payne, Michael A Portman, Hengameh Raissy, Isabelle G Randall, Suchitra Rao, Harrison T Reeder, Johana M Rosas, Mark W Russell, Arash A Sabati, Yamuna Sanil, Alice I Sato, Michael S Schechter, Rangaraj Selvarangan, S Kristen Sexson Tejtel, Divya Shakti, Kavita Sharma, Lindsay M Squeglia, Shubika Srivastava, Michelle D Stevenson, Jacqueline Szmuszkovicz, Maria M Talavera-Barber, Ronald J Teufel, Deepika Thacker, Felicia Trachtenberg, Mmekom M Udosen, Megan R Warner, Sara E Watson, Alan Werzberger, Jordan C Weyer, Marion J Wood, H Shonna Yin, William T Zempsky, Emily Zimmerman, Benard P Dreyer, RECOVER-Pediatric Consortium

Get full text

Descriptive Analysis of Pediatric Studies Included in the European Union Post-Authorization Study Register from 2010 to 2023 by Annalisa Landi, Giorgio Reggiardo, Antonella Didio, Annunziata D’Ercole, Adriana Ceci, Grace Shalom Govere, Donato Bonifazi, Fedele Bonifazi, Salvatore Crisafulli, Gianluca Trifirò, Florentia Kaguelidou, Katja Marja Hakkarainen, Katarina Gvozdanović, Francesco Barone-Adesi, Andrealuna Ucciero, Mariagrazia Felisi

Get full text

Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine by Nikolai Petrovsky

“…Following a successful pediatric study, its approval was extended to children 5 years and older. …”
Get full text

Oral microbiota dysbiosis in pediatric patients undergoing treatment for acute lymphoid leukemia a preliminary study by André Vieira Souza, Leonardo Vinícius Barbosa, Alejandra Adriana Cardoso de Castro, Edna Kakitani Carboni, Flora Mitie Watanabe, Roberto Rossati, Libera Maria Dalla Costa, Dany Mesa, Cleber Machado-Souza

“…Chemotherapy administered to these patients may induce a substantial imbalance in the oral microbiota. A prospective pediatric study encompassing a control group (without ALL) and ALL patients at two treatment stages (pre-induction and consolidation) was conducted. …”
Get full text

Precaution or barrier? Reconsidering contact and isolation measures in palliative care: a systematic scoping review by Henry T. He, Shannon Bunn, Brittany Rance

“…No study directly evaluated the efficacy of contact precautions in reducing antimicrobial-resistant organism (ARO) transmission, though one pediatric study reported liberal protocols and no nosocomial ARO infections. …”
Get full text

Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology by Alan D Irvine, Amy S Paller, Emma Guttman-Yassky, Eulalia Baselga, Marjolein de Bruin-Weller, Shyamalie Jayawardena, Annie Zhang, Paola Mina-Osorio, Elena Rizova, Zafer E Ozturk

“…Hence, an observational study is needed to evaluate AD characteristics and progression in paediatric patients with moderate-to-severe AD.Methods and analysis Pediatric Study in Atopic Dermatitis (PEDISTAD) is a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe AD who are currently receiving systemic or topical treatment and whose disease is not adequately controlled by topical prescription therapies or for whom those therapies are not medically advisable. 1300 children at 100–150 sites in approximately 20 countries worldwide will be enrolled and followed for 5 years. …”
Get full text

An insight into the relationships between hepcidin, anemia, infections and inflammatory cytokines in pediatric refugees: a cross-sectional study. by Sarah Cherian, David A Forbes, Angus G Cook, Frank M Sanfilippo, Erwin H Kemna, Dorine W Swinkels, David P Burgner

“…<h4>Conclusions/significance</h4>This is the largest pediatric study of the in vivo associations between hepcidin, iron status and cytokines. …”
Get full text

Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years by Andreas Wollenberg, Masanori Ikeda, Chia-Yu Chu, Lawrence F. Eichenfield, Marieke M. B. Seyger, Apurva Prakash, Robinette Angle, Danting Zhu, Marco Pontes, Amy S. Paller

“…Background Baricitinib, an oral selective Janus kinase inhibitor, improved clinical signs and symptoms of moderate-to-severe atopic dermatitis (AD) at week 16 in the phase 3 pediatric study BREEZE-AD-PEDS.Objective To assess longer-term efficacy and safety of baricitinib in pediatric patients aged 2 to <18 years.Methods In BREEZE-AD-PEDS long-term extension, responders and partial responders (validated Investigator Global Assessment-Atopic Dermatitis [vIGA-AD®] 0/1/2) at Week 16 remained on double-blind treatment to which they were randomized (placebo, baricitinib [1-mg equivalent, 2-mg equivalent, or 4-mg equivalent); non-responders (vIGA-AD 3 or 4) at Week 16 transitioned to open-label baricitinib 4-mg equivalent. …”
Get full text

Dupilumab in children with eosinophilic esophagitis: a retrospective multicenter study by Mohammed Hasosah, Ghassan Sukkar, Asharf AlSahafi, Ali Zaidan, Nouf Ghous, Abdulmajed Alshahrani, Ziyad Al Zahrani, Naif Hasosah, Mansour Qurashi, Loie Goronfolah, Ali Alsharief, Nagla Kamal

“…Dupilumab had a well-tolerated safety profile, except for one patient who developed conjunctivitis. Conclusion This pediatric study demonstrates the effectiveness of dupilumab as a second-line therapy for symptom relief, and endoscopic and histological improvements of EoE that is refractory to current treatment. …”
Get full text

Landscape of Post-Marketing Requirements Under the Pediatric Research Equity Act for Antibiotics from 2009–2024 by Daniel Selig, Funmi Aminu, Sue Cammarata, Ting Chen, Lauren Dolak, Stephen Duprez, Stephanie Ecker, Lisa Gault, Sandra George, Margaret Harkins, Clayton Litchmore, Michael Serenko, William Waverczak, Doug Girgenti

“…Of the 44 remaining PMRs in the analysis set, the median pediatric study follow-up time from adult approval was 5.3 years (range 0.94 to 11.5 years), with a study completion rate of 54.5% (N = 24). …”
Get full text

Cost-effectiveness analyses of 20-valent pneumococcal conjugate vaccine in children and adults: A narrative review by Aiko Shono, Shu-Ling Hoshi, Masahide Kondo

“…We included 26 CEAs (17 in adults, nine in children) from 15 countries in this review. Eight of the pediatric studies and 11 of the adult studies concluded that PCV20 strategy would be cost-saving compared with existing vaccine(s), in at least one comparison. …”
Get full text

Mitigated Clinical Course of Crescentic Glomerulonephritis with Positive Anti-Glomerular Basement Membrane Antibodies in a 14-Year-Old Girl by Noortje M. Van Der Meulen, Michiel J.S. Oosterveld, Marjolijn S.W. Quaak, Ester M.M. van Leeuwen, Joris J.T.H. Roelofs, Rik Westland

“… Introduction: Anti-glomerular basement membrane (anti-GBM) glomerulonephritis is associated with severe kidney failure and high morbidity and is exceedingly rare in children. The few pediatric studies published about this condition report dependency of kidney replacement therapy at presentation and partial or complete response in kidney function in a minority of cases. …”
Get full text

Fascial plane blocks in pediatric anesthesia: A narrative review by Nur N. Yucal, Can Aksu

“…Despite the numerous benefits demonstrated in pediatric studies, the implementation of regional anesthesia in children remains insufficiently adopted in clinical settings. …”
Get full text

Evaluating the Equity of Female Representation for Determining the Safety and Efficacy of Ibuprofen: An Analysis of the Supporting Evidence for Canadian Ibuprofen Product Monograph... by Kiriana Blackwell, Nicole Tegg, Jenna Semmens, Sofia B. Ahmed, Colleen M. Norris

“…Studies reporting on secondary data, animal studies, pediatric studies, and studies where the full text was unavailable were excluded. …”
Get full text

An Assessment of Harm in Adults—Adverse Childhood Experiences Screening in Primary Care: A Survey-Based Study by Katelyn M. Inch MSc, Craig Olmstead MD, CCFP, Brenna A. Kaschor MD, PhD, CCFP

“…The Adverse Childhood Experiences Questionnaire (ACE-Q) screens for adverse childhood experiences (ACEs), which are linked to increased disease risk. Although pediatric studies report no adverse effects of ACE-Q use, primary care data is limited. …”
Get full text

Estudo comparativo de descritor de dose em exames pediátricos de tomografia computadorizada by Jerusa Finatto, Ana Paula Pastre Froner, Juliana Pimentel, Ana Maria Marques da Silva

“…Most CT scanners display a dose index, CTDIvol. For pediatric studies, this dose index is measured using a standard phantom and an ionization chamber, and does not represent patient dose, but a reference measurement. …”
Get full text

Bibliometric characteristics of retracted publications in pediatrics research: a systematic review by Zhi-Yi Yang, Li-Li Yang

“…Excluded from the review were articles unrelated to pediatric studies, conference proceedings, non-English articles, duplicates, and articles that could not be identified. …”
Get full text

7T MRI in the evaluation of ischemic stroke: a systematic review by Felix Tobias Kurz, Felix Tobias Kurz, Daniela Dumitriu La Grange, Daniela Dumitriu La Grange, Daniele Botta, Maria Isabel Vargas, Francois Lazeyras, Myriam Edjlali-Goujon, Jean-Pierre Pruvo, Isabel Wanke, Isabel Wanke, Isabel Wanke, Karl-Olof Lövblad, Karl-Olof Lövblad

“…Studies on 7T MRI in adult ischemic stroke patients were included; exclusions were non-human, post-mortem, or pediatric studies.ResultsWe identified 16 studies on the use of 7T MRI for prolonged periods after stroke symptom onset, highlighting its higher spatial resolution for depicting ischemic lesions and vascular imaging. …”
Get full text

ADHD in Adults with Epilepsy: A Guide for Neurologists by Luciana Giambarberi, Halley B. Alexander, Heidi Munger Clary

“…Although the management of ADHD in PWE has been debated due to perceived seizure risk related to ADHD medications, a consensus has developed based on early pediatric studies that support the treatment of ADHD. However, the management of adults with ADHD, particularly in PWE, remains relatively unexplored. …”
Get full text

Approaches and outcomes of adalimumab discontinuation in patients with well-controlled inflammatory arthritis: a systematic search and review by Erin Balay-Dustrude, Jessica Fennell, Kevin Baszis, Y. Ingrid Goh, Daniel B. Horton, Tzielan Lee, Chloe Rotman, Anna Sutton, Marinka Twilt, Olha Halyabar, for the CARRA JIA Inactive Disease Workgroup

“…There was notable variability in study design, follow-up duration, specificity for TNFi results, and controlled pediatric studies. Conclusion The literature evaluating adalimumab and other TNFi discontinuation, flare rates, and recapture success within the inflammatory arthritis population demonstrated less flare when medications were tapered, over abrupt stop in the RA, spondyloarthropathy, and JIA populations. …”
Get full text